Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone +/- Metronidazole to Reverse Abiraterone Resistance in mCRPC
NCT06616597Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2025
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of metronidazole in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: PSA30 response at 24 weeks. Started Feb 2025; status: recruiting.
02
Drugs
metronidazole
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06616597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616597.